U.S. markets closed

  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     

  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     

  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     

  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     

  • Crude Oil

    110.35
    +0.46 (+0.42%)
     

  • Gold

    1,845.10
    +3.90 (+0.21%)
     

  • Silver

    21.87
    -0.03 (-0.13%)
     

  • EUR/USD

    1.0562
    -0.0026 (-0.24%)
     

  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     

  • GBP/USD

    1.2496
    +0.0021 (+0.17%)
     

  • USD/JPY

    127.8500
    +0.0560 (+0.04%)
     

  • BTC-USD

    29,286.27
    -1,159.91 (-3.81%)
     

  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     

  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     

  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Global Biopharmaceutical CMO And CRO Market Research Report 2022 - ResearchAndMarkets.com

·4 min read

DUBLIN, January 27, 2022--(BUSINESS WIRE)--The "Biopharmaceutical CMO And CRO Market Size, Share & Trends Analysis Report by Source (Mammalian, Non-mammalian), by Service (Contract Manufacturing, Contract Research), by Product, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6%

Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.

For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future.

The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs & CROs to accelerate their business operations.

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs.

However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.

Biopharmaceutical CMO & CRO Market Report Highlights

  • Non-mammalian cell line-based bioproduction system is expected to be the fastest-growing segment over the forecast period

  • Innovative strategies are being implemented to identify and explore the potential of various microbes

  • This can be attributed to increasing investments in research programs for the development of novel therapeutics

  • The market in North America is recognized as a leader in biopharmaceutical innovations, thereby resulting in a large share of 33.97%

  • Moreover, the presence of several service providers and a higher concentration & number of biopharmaceutical firms in the region supports the market growth

  • The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities

Industry Outlook: Market Variables, Trends, & Scope

Trend Analysis

  • Source trend

  • Service trend

  • Product trend

  • Regional trend

Market driver analysis

  • Rising investment by CMOs for capacity expansion

  • Commercial success of biopharmaceuticals and consequent increased demand for the biopharmaceuticals

  • Robust biopharmaceuticals pipeline

  • Cost and time saving benefits offered by contract services

Market restraint analysis

  • Limited outsourcing amongst well-stablished biopharmaceutical manufacturer

Key Opportunity Analysis

  • Rising funds in biopharmaceutical industry

  • Mergers & acquisition for facility expansion

  • Growing demand for protein therapeutics

Industry Analysis-Porter's

  • Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power

  • Buyer Power: Fragmented nature of biopharmaceutical industry has led to moderate bargaining power of buyers

  • Substitution Threat: High due to presence of several big pharma companies

  • New Entrants Threat: Presence of established players coupled with need of adequate capacity results in moderate threat of new entrants

  • Competitive Rivalry: High due to fragmented nature of market

Biopharmaceuticals CMO & CRO-SWOT Analysis, By PEST

Biopharmaceuticals CMO & CRO Market: Company Share Analysis

Competitive Landscape

  • Strategy Framework

  • Company Categorization

  • New Entrants

  • Mature Players & Leaders

Trends In Biopharmaceutical Industry

R&D Landscape Of Biopharmaceuticals

Customer Relationship Management In Contract Manufacturing

  • Selection process of CMO

  • Operations and quality oversight of CMOs

Companies Mentioned

  • Boehringer Ingelheim GmbH

  • LONZA

  • Inno Biologics Sdn Bhd

  • Rentschler Biotechnologie GmbH

  • JRS PHARMA

  • BIOMEVA GmbH

  • ProBioGen

  • UJIFILM Diosynth Biotechnologies U.S.A., Inc.

  • TOYOBO CO., LTD.

  • Samsung BioLogics

  • Patheon

  • CMC Biologics

  • Binex Co., Ltd.

  • WuXi Biologics

  • AbbVie, Inc.

  • Charles River Laboratories International, Inc

  • ICON plc.

  • Pharmaceutical Product Development, LLC

  • LabCorp

  • Parexel International Corporation

  • PRA Health Sciences

For more information about this report visit https://www.researchandmarkets.com/r/8gu922

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005546/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Recommended Stories

  • Why I'm Not Worried About the Stock Market Crash

    It's important to remember that as we watch the stock market crash and our personal net worth take a big hit. While that has certainly happened, it's important to note that the stock market isn't the economy.

  • Why Tesla Stock Was Slammed on Friday

    Shares of Tesla (NASDAQ: TSLA) sank on Friday, declining as much as 10.8% at one point during the trading day. The electric-car maker stock's beating was likely driven primarily by a tough day in the market for many stocks -- particularly for growth stocks like Tesla. The stock's downward trend has largely been tied to investors' skittishness toward highly valued growth stocks.

  • Billionaire Ray Dalio Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

    When legends speak, people listen – and few investors match the legendary status of Ray Dalio. The founder of Bridgewater Associates has built his firm from a 2-room apartment operation into the world’s largest hedge fund, with more than $150 billion in assets under management, and a net gain exceeding $46 billion. Dalio believes that the next two to four years will see our global economic and political systems change in ways that are unpredictable now. And the key to survival, for investors, ma

  • The odds of a home price correction just spiked—this interactive chart shows if your local housing market is at risk

    Over the past month, the odds of a home price correction spiked. That's according to an analysis CoreLogic ran for Fortune this week.

  • Tesla Loses Top Spot in Cathie Wood’s Flagship Fund. This Stock Is the New No. 1.

    Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.

  • How To Generate $100,000 Of Retirement Income, Without Selling Principal

    Your retirement savings are $1 million. You want $100,000 of yearly retirement income, including Social Security. Is that doable without tons of risk?

  • It May Be a Bear Market, But It’s Not a Panic. That’s Worrisome

    (Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesStocks Avert Bear Market, Slide for Seventh Week: Markets WrapRuble Hits 5-Year High as

  • 10 Best Buy-the-Dip Tech Stocks According to Billionaire Ken Fisher

    In this article, we discuss 10 buy-the-dip stocks to buy according to billionaire Ken Fisher. If you want to skip our detailed analysis of Fisher’s stock selection and the current sell-off in tech, go directly to 5 Best Buy-the-Dip Tech Stocks According to Billionaire Ken Fisher. The tech-heavy Nasdaq Composite is down 27% in 2022 […]

  • Damage after Gaylord tornado

    Damage after Gaylord tornado, courtesy Sarah Fake

  • Dow Jones Futures: Market Correction Getting Worse, Tesla Breaks Down; What You Must Do Now

    Another week of big losses as Wall Street adjusts to a "hard" reality. Tesla broke decisively, but it wasn't alone.

  • Which Top-Performing Dividend Stocks Look Most Attractive?

    High-yield dividend stocks have been viewed more favorably than high-multiple growth stocks these days. After yet another month of excessive market-wide selling, the yields of many top dividend stocks are slightly richer. As the Fed raises interest rates further, growth and value could continue to get slammed. This week, the Fed signaled that it's more than willing to keep the rate hikes coming until inflation backs down, even if it means jeopardizing a "soft landing" and inflicting more pain in

  • Yes, Nvidia Stock is Expensive — But Oppenheimer Says It’s Worth the Price

    In less than week -- Wednesday, May 25 -- Nvidia (NVDA) is due to report its Q1 2022 earnings. Analysts on average are optimistic about the report itself, and also about the guidance Nvidia might give, predicting Nvidia will report 43% growth to $1.30 per share this quarter, and promise investors another 31% worth of growth ($1.36 per share) next quarter. And one analyst thinks Nvidia could do even better than that. Previewing next Wednesday's earnings report, Oppenheimer's Rick Schafer reiterat

  • The most advanced treatments for monkeypox were developed to address the wrong threat

    The markets may be in free fall, but a few biotechnology companies had an exceptionally good day. Siga’s stock is up more than 40%; Emergent Biosolutions’s gained nearly 12%, and Tonix Pharmaceuticals, 15%. A few cases of monkeypox have been registered in Europe and North America, far from West and Central Africa where outbreaks typically emerge.

  • A bear-market rally could be lurking, but investors should ‘sell any rips,’ says Bank of America

    Bank of America strategists advise investors keep buying any bounces higher for the stock market, as capitulation isn't quite here yet.

  • Why Ford Stock Got Crushed by the Market Today

    What happened The ride in Ford (NYSE: F) stock wasn't very smooth on Friday. The big American carmaker saw its shares decline by nearly 3% on a day when the S&P 500 index essentially traded sideways. A ruling from a court overseas was the key catalyst in that deceleration.

  • 10 Costco Brand Items With the Best Bargains in May

    Back in 1976, Costco was just starting out and existed as a single location in San Diego, California. Fast forward 45 years later and you've got one of the most epic retail institutions around, with...

  • Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

    Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.

  • Nasdaq Bear Market: 4 Phenomenal Growth Stocks You'll Regret Not Buying On the Dip

    These fast-growing stocks are ripe for the picking following a nearly 30% peak decline in the Nasdaq.

  • Lagarde Says Crypto Is ‘Worth Nothing’ and Should Be Regulated

    (Bloomberg) -- European Central Bank President Christine Lagarde said crypto-currencies are “based on nothing” and should be regulated to steer people away from speculating on them with their life savings.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesStocks Avert Bear Market, Slide for Seventh Week: Markets WrapRuble Hits 5-Year High as Gas Buyers Bend to Putin’

  • The Market Is Melting Down and People Are Feeling It. ‘My Stomach Is Churning All Day’

    Many are watching the investments they meant for down payments, tuition or retirement shrink day after day.